Building future
worth through data
Creating future worth through data.
worth through data
Total 186 Posts
-
Daehan Nupharm Earns an ‘A’ Rating in Sustinvest’s ESG Assessment- Recognized for Social Responsibility and Ethical Management Practices… Strengthening the Foundation for Sustainable Management- Demonstrating Non-Financial Competitiveness Through the Advancement of ESG Management SystemsThe company announced on the 18th through media reports that it had received an A rating (Excellent Company) in the corporate ESG assessment conducted by Sustinvest, a domestic ESG rating agency, in recognition of its efforts to fulfill social responsibilities and practice ethical management as part of its commitment to sustainable business practices.ESG (Environmental, Social, and Governance) refers to a set of criteria used to evaluate a company's non-financial performance in the areas of environment (E), social responsibility (S), and corporate governance (G). ESG has increasingly become a key standard for assessing corporate sustainability and social responsibility. In particular, within the pharmaceutical industry, transparent management systems, ethical business practices, and the ability to fulfill social responsibilities are becoming just as important as product quality and safety. These factors are also reflected as key evaluation criteria in assessments such as the Innovative Pharmaceutical Company certification program.Building on the results of this ESG assessment, the company plans to further strengthen its commitment and role in promoting sustainable management. To this end, it will establish a transparent and fair management system, embed ethical management practices into its corporate culture, and continue to fulfill its social responsibilities by building trust with a wide range of stakeholders.The company stated, “Receiving an A rating in Sustinvest’s ESG assessment is particularly meaningful as it recognizes Daehan Nupharm’s efforts toward sustainable management. Going forward, we will continue to uphold ethical management and social responsibility as core corporate values and strengthen our social value and foundation for sustainable growth through transparent and responsible management.”2026.11.18 -
‘Cindella ComfyTox’ Skin Booster Unveiled at Cosmoprof Asia Hong Kong... Company Ramps Up Global Aesthetic Market Expansion- A high-tech solution combining a botulinum light chain with adenosine to simultaneously improve skin texture and elasticity.- Designed with a non-toxic, non-paralyzing light chain peptide, eliminating concerns regarding resistance or toxicity even with repeated treatments.- Enhanced anti-wrinkle efficacy backed by clinical data on cellular and skin penetration. On the 13th, the company unveiled ‘Cindella ComfyTox’—a strategic new product under its flagship brand, ‘Cindella’—at Cosmoprof Asia Hong Kong, the largest beauty trade show in Asia, signaling an aggressive push into the global medical aesthetic market. Cindella ComfyTox is a premium skin booster that integrates a botulinum light chain with adenosine, an ingredient known for its anti-wrinkle properties. It addresses both skin texture and elasticity, smoothing out rough skin and fostering firm, resilient skin from within. A key differentiator of this new product lies in its safety and versatility. As a skin booster rather than a pharmaceutical drug, Cindella ComfyTox utilizes a light chain peptide that is both non-toxic and non-paralyzing. It was developed to soften the appearance of expression lines—often caused by repetitive facial movements—while simultaneously enhancing skin elasticity and refining overall skin texture. Furthermore, the product features a unique molecular design that eliminates neurotoxic activity, thereby reducing the risk of developing resistance or toxicity even with repeated use. Through our participation in Cosmoprof Hong Kong, we have once again confirmed the high demand for and strong standing of K-beauty and medical aesthetics in the global market. We intend to aggressively expand our export footprint in the global aesthetics sector, led by "Cindella ComfyTox"—a solution that safely improves both skin elasticity and texture without concerns regarding toxins or the development of resistance.2026.11.13 -
Cumulative Revenue for the First Three Quarters Reaches 160.4 Billion KRW... Increased Investment in New Facilities and R&D- Debt-to-equity ratio improved to 87.8%... Progress made in debt repayment and financial structure stabilization- Temporary decline in profitability due to the operation and trial production at a new facility, alongside expanded R&D investment We announced on the 12th that its cumulative revenue for the first three quarters reached 160.4 billion KRW, marking a 6.5% increase compared to the same period last year. Net profit for the period stood at 9 billion KRW—a 10.1% year-on-year increase—with a net profit margin of 5.6%, reflecting a stable profit structure. Operating profit was recorded at 2.2 billion KRW, a decrease from the same period last year. The company explained that this was due to a temporary rise in fixed costs following the launch of a new production facility, as well as increased investment in research and development (R&D) to secure future growth drivers. To expand production capacity in line with global manufacturing guidelines, the company is currently operating both its existing and new facilities. The cost of goods sold (COGS) ratio increased due to a combination of factors, including fixed costs associated with this dual-facility operation, expenses related to trial production, and higher costs for raw materials and supplies driven by a strong exchange rate. Furthermore, the company continues to scale up its R&D investment to lay the groundwork for future growth. R&D expenditures reached 7.9 billion KRW, an increase of 24.8% compared to the same period last year. Our financial structure has become more stable. By proactively addressing interest rate volatility and shifts in the financial environment, the company has improved its financial soundness through ongoing debt repayment and effective management of receivables. Borrowings incurred during the construction of the new factory are being gradually reduced through partial early repayments, while equity has increased by 2.9 billion KRW, driven in part by a 7.6 billion KRW rise in retained earnings. Consequently, the debt-to-equity ratio improved by approximately 6.0 percentage points year-on-year to 87.8%, and the current ratio rose by 15.0 percentage points to 170.2%, ensuring stable liquidity. We further stated, "We participated in CPHI Worldwide and Cosmoprof Asia (Hong Kong) to expand our presence in overseas markets for wellness injectables—specifically those targeting vitamins, immunity, metabolic diseases, and beauty." They added, "We plan to secure new growth momentum by exploring global markets and increasing our exports."2026.11.13 -
Exhibition Featuring the Unique Artistic Worlds of Three Artists with Disabilities- An artistic realm shaped by distinct senses and perspectives... sharing the values of diversity and inclusion In collaboration with the cultural and arts organization "ARTROOM VERSI," our company has hosted an art exhibition titled *Ahead, Beside, and Following* (*Apseo, Gyeoteseo, Ttaraseo*), designed to showcase the original artistic worlds of artists with disabilities and to share the values of diversity and empathy. The exhibition is being held from November 1st to 10th at the Daehan Nupharm Industry-Academia-Research Center in Pangyo, Seongnam, Gyeonggi Province. It features works by three artists from different generations: Lee Hee-moon, Kim Woo-sol, and Kim Ju-won. By presenting the works of these artists—who each engage with the world in their own unique way, drawing from their distinct life experiences and sensory perspectives—the exhibition highlights the diversity and possibilities of artistic expression. It aims to create a space where visitors can connect, share various emotions, and exchange thoughts through the medium of art. The title, *Ahead, Beside, and Following*, reflects the idea of artists serving as companions to one another, growing together as they navigate their lives and creative work. An artist who has forged a path ahead demonstrates new possibilities to those who come after, while the artists who follow discover their own unique colors and directions. This conveys a message of solidarity—a mutual recognition and support for one another’s potential that transcends generational boundaries. Distinct Artistic Worlds Unfolded by Three ArtistsLee Hee-moon (born 1986) has, since childhood, consistently depicted subjects that capture his interest—ranging from airplanes and airports to flowers, birds, trees, animals, and the landscapes of villages where families reside. Centeredon nature and living beings, his work employs bold yet delicate lines and colors to construct unique, imaginative landscapes. A defining characteristic of the work is the repeated depiction of the same subject, with each iteration revealing new forms and color palettes. Born in 2003, artist Kim Woo-sol draws upon an exceptional visual memory to reconstruct images from personal experience and observation, as well as from renowned masterpieces. A pivotal moment in the development of his artistic vision was encountering Claude Monet’s Water Lilies at the Musée de l’Orangerie in France. By reinterpreting various art-historical styles—such as Impressionism and Cubism—through his own unique sensibility, he creates original compositions that weave together classic masterpieces, contemporary figures, memories, and personal experiences. Born in 2016, artist Kim Ju-won is building a distinct body of work rooted in an intuitive and unconstrained visual language. His pieces are marked by bold colors, sweeping brushstrokes, and the harmonious interplay of contrasting hues—such as blue with orange, or green with yellow. Unbound by rigid rules or formal conventions, he explores his artistic potential by freely expressing the sensations of the moment through the movement of his hands. The Value of Empathy and Coexistence Through ArtThis exhibition goes beyond the simple act of viewing art, it highlights the importance of understanding and respecting diverse sensibilities and modes of expression. In particular, the way these three artists pursue their creative endeavors alongside one another illustrates the significance of artistic camaraderie and the potential for a sustainable way of life. Through this exhibition, we have transformed its corporate space into a venue for communication—using art and culture as a medium—allowing employees and visitors alike to share in the values of diversity and empathy.2026.11.05 -
New Zealand Naturalist Brand ‘Harker Herbals’ to Reach Korean Consumers via Lotte Home Shopping’s ‘Choi Yu-ra Show’Harker Herbals, a New Zealand-based naturalist health supplement brand, will be introduced to Korean consumers through ‘Choi Yu-ra Show’—a flagship program on Lotte Home Shopping—on Thursday, November 5, at 8:45 PM. This live broadcast will feature the brand’s core products, imported directly from New Zealand, and will serve as an opportunity to showcase Harker Herbals’ naturalist philosophy and competitive product offerings to the Korean market. ■ Harker Herbals: A Naturalist Brand Found in Over 1,000 Pharmacies and Health Stores Across New Zealand Harker Herbals is a naturalist health supplement brand available in over 1,000 pharmacies and health stores throughout New Zealand.The brand develops its products using a variety of plant-based ingredients and herbs derived from nature, having firmly established its presence among local New Zealand consumers and through pharmacy retail channels.Harker Herbals distinguishes itself through a product development approach that highlights the unique properties of natural ingredients, underpinned by a brand philosophy centered on the use of herbs.As interest in health supplements based on natural, plant-derived ingredients and herbs continues to grow in Korea, Harker Herbals is gaining attention as a premium naturalist wellness brand. The upcoming broadcast will feature products manufactured in New Zealand and imported directly to Korea, highlighting the brand’s unique strengths in ingredient quality and its core values.● Deep Refresh Essential This product features a blend of 10 plant-based ingredients and essential oils, carefullyed by Malcolm Harker—a herbalist and the founder of Harker Herbals. It is distinguished by a unique formulation that leverages the inherent properties of its natural ingredients.Designed for convenience, the product comes in a bottle, making it an ideal addition to one’s daily wellness routine. ■ Featured on Lotte Home Shopping’s Flagship Program, "Choi Yu-ra Show" The product will be showcased on the "Choi Yu-ra Show," one of Lotte Home Shopping’s premier programs.Hosted by presenter Choi Yu-ra, the show focuses on product quality, brand storytelling, and providing information from the consumer’s perspective and it has long served as a platform for introducing various premium brands and unique, high-quality products.Through this broadcast, Harker Herbals aims to highlight its identity as a New Zealand-based natural wellness brand and showcase the competitive edge of its products, while expanding its reach to domestic consumers. We stated, "Consumers’ criteria for choosing health products have evolved, they now look beyond simple functionality to consider the origin and quality of ingredients, as well as the overall credibility of the brand."We added, "Harker Herbals offers distinct wellness products rooted in natural ingredients and a brand reputation built over years in New Zealand." We further noted, "Starting with this live broadcast on Lotte Home Shopping’s 'Choi Yu-ra Show,' we plan to boost our brand awareness among domestic consumers and strengthen our position in the premium natural health product market."■ Available to watch live via Lotte Home Shopping TV and mobile app This broadcast will be available to watch in real-time on Thursday, November 5, 2026, at 8:45 PM, via the Lotte Home Shopping TV channel and mobile app.During the broadcast, a variety of product bundles—centered around key items from Harker Herbals—will be offered, along with special benefits exclusive to the broadcast. [Broadcast Information]Date & Time: Thursday, November 5, 2026, at 8:45 PMChannel: Lotte Home Shopping TV / Mobile AppProgram: Choi Yura Show LIVEBrand: Harker HerbalsFeatured Product: Deep Refresh Essential Go to the live broadcast:http://www.lotteimall.com//contstmpl/viewContsTmplDetail.lotte?conts_no=732026.11.05 -
Q2 Revenue Reaches KRW 101.7 Billion, Posting 8.93% YoY GrowthIn the second quarter of this year, Daehan Nupharm continued its growth, recording revenue of KRW 101.7 billion, an 8.93% increase compared to the same period last year. Notably, net profit surged by 155.32% YoY to KRW 5.58 billion, demonstrating strong bottom-line performance.On the other hand, operating profit for the second quarter stood at KRW 7.3 billion, down 27.64% YoY. This decrease was primarily driven by an increase in cost-of-goods-sold (COGS) ratio, resulting from higher fixed costs associated with the operation of the new manufacturing facility, alongside rising import costs for raw and subsidiary materials amid ongoing foreign exchange rate pressures.Despite external uncertainties—including the initial cost absorption of the new plant and persistent high exchange rates—Daehan Nupharm achieved meaningful results with substantial net profit growth. In the second half of the year, we plan to focus on cost structure optimization while expanding revenue driven by high-value-added products.2026.08.14 -
Launch of 'Qvecin Inj.', a Long-Acting Antibiotic Approved by the U.S. FDAWe have launched 'Qvecin Inj.', a long-acting injectable antibiotic for companion animals. Qvecin is a prescription veterinary medicinal product containing cefovecin sodium (80 mg/mL) as its active ingredient, and is a broad-spectrum antibiotic that can be used to treat bacterial skin infections and urinary tract infections in dogs and cats. Its most notable feature is that a single subcutaneous injection provides therapeutic effects for up to 14 days. It reduces the burden of repeated drug administration for both pets and their owners, improves treatment compliance, and enables veterinary clinics to establish more efficient treatment plans. In particular, Qvecin Inj. has been approved as a First Generic (under U.S. FDA standards), having undergone the FDA’s stringent evaluations of quality, safety, and efficacy for both the raw material and the finished product. This is significant in that it is a long-acting antibiotic that meets international quality standards. Based on its rapid absorption characteristics, it reaches effective blood concentration within approximately 30 minutes after administration, and it has been designed with safety in mind even for repeated dosing. After reconstitution (dissolution), it can be used for up to 28 days when stored under refrigeration, thereby enhancing convenience for use in veterinary clinics. Qvecin Inj. not only provides effective treatment but also reduces the burden on both pet owners and animals, and we plan to continue supplying differentiated veterinary medicinal products that meet the needs of clinical practice.2026.07.01 -
Q1 Revenue Hits KRW 54.8 Billion, Up 5.8% YoYOur consolidated revenue for the first quarter of this year reached KRW 54.8 billion, representing a 5.8% increase compared to the same period last year (KRW 51.9 billion). During the same period, net income stood at KRW 3.0 billion, achieving a double-digit growth rate of 16.3% year-over-year (from KRW 2.6 billion), demonstrating a simultaneous improvement in both top-line expansion and profitability. However, operating profit came in at KRW 3.1 billion, reflecting a temporary decline driven by rising cost of goods sold (COGS) and increased R&D investments aimed at securing the company's mid-to-long-term growth engines.We are currently conducting the qualification process for our newly constructed manufacturing facility, with the goal of bringing the injectable production lines fully operational by early next year. This expansion in production capacity is expected to accelerate our top-line growth. In response to this upcoming capacity boost, we are actively strengthening our sales organization and plan to focus all efforts on converting the increased production volume and new product pipeline into revenue starting in 2027.2026.05.14 -
Showcases Products at Tashkent Medical Exhibition 2026, Expands CIS Market OutreachWe announced that it participated in the “Tashkent International Healthcare Exhibition 2026,” held from April 28 to 30 in Tashkent, Uzbekistan, where it showcased a range of products and engaged with local buyers to strengthen its presence in the Central Asian market.The company has already registered several products, including Luthione injection, with the Uzbek regulatory authority and is actively exporting to the country. During the exhibition, We met with potential buyers not only from Uzbekistan but also from neighboring CIS countries, introducing its product portfolio and exploring new business opportunities.Pharmaceutical trends in the CIS region have recently been shifting beyond basic treatments toward non-reimbursable wellness injectables and clinic-specialized products. We focused its promotion on these products, where it holds a competitive edge over other pharmaceutical companies, receiving an enthusiastic response from local medical professionals and distributors.In particular, following the recent tightening of pharmaceutical registration regulations in Uzbekistan, closer collaboration with local partners and thorough preparation of regulatory documentation have become increasingly important. The company focused on discussing these key issues with local partners during the event to further refine its market entry strategy.The Tashkent International Healthcare Exhibition is regarded as the largest healthcare exhibition in the CIS region, attracting numerous pharmaceutical and medical device companies worldwide, and is considered a key platform for entering the CIS market.2026.05.07


Home